Introduction {#s1}
============

According to the World Alzheimer's Report 2018, 50 million people are living with dementia worldwide ([@B1]), and Alzheimer's disease (AD) accounts on its own for almost 2/3 of all dementia cases. AD is a devastating neurodegenerative disease characterised by progressive cognitive impairment, usually affecting, at the beginning, episodic memory. As the disease progresses, other cognitive domains become affected, leading to the loss of independence. Behavioral and psychological symptoms in dementia (BPSD) are a group of behavior, mood, perception, or thought disturbances manifesting with anxiety, agitation, delusions and hallucination ([@B2]). The incidence of perceptual abnormalities in patient with dementia is high; around 20% of subjects with no behavioral symptoms at the diagnosis will develop some of them within 2 years ([@B2]). Experiencing BPSD leads to institutionalization, greater cognitive impairment, worse quality of life and carers' distress, increased mortality ([@B3]), prolonged in-hospital stay, and more difficult discharge ([@B4]). The features of the psychiatric symptoms in AD usually differ from the ones in other psychiatric disorders. Compared to schizophrenia, delusions in AD are simpler, mostly characterized by misbelief, distrust about family members, theft, and suspiciousness of abandon ([@B5]). Hallucinations in AD are usually visual ([@B6]), more rarely somatic and olfactory ([@B7]). Agitation has been related to structural and functional impairment of emotional circuits, leading, for example, to increased perception of threat ([@B6]).

Unfortunately, the management of BPSD is complicated and challenging; the available licensed treatment is limited, the success of the therapy varies, and the spectrum of possible adverse events limits the choices ([@B8]). The preferred approach is the non-pharmacological one; however, despite multiple studies, there is not enough homogeneity in sample size, intervention adopted and follow-up period ([@B2]). An evidence-based algorithm has recently been designed and proposed by multidisciplinary teams, to better manage behavioral symptoms and lead clinicians on the therapeutic choice ([@B4]).

In this review we evaluate the use of antipsychotic drugs in AD. The search was conducted in PubMed and Scopus, with keywords and search criteria as detailed in the [**Supplementary Material**](#SM1){ref-type="supplementary-material"}.

Antipsychotic Drugs {#s1_1}
-------------------

Antipsychotic drugs can be divided in two groups: typical and atypical, depending on their strength as antagonists to dopamine D2 receptors, higher for the typical ones, and to the 5-hydroxytryptamine-A (5-HT2A) receptors, characteristic of the atypical ones ([@B9]). Among the typical antipsychotic category, haloperidol remains the most prescribed; several concerns have been raised because of their low safety profile. Sedation, extrapyramidal symptoms (EPS), orthostatic hypotension, and anticholinergic effects were concerning safety issues, mainly due to the strong and long-lasting binding of D2 receptors across the whole brain regions, together with several other receptors ([@B5]). Risperidone, olanzapine, and quetiapine are atypical neuroleptics. The binding to D2 receptors is more targeted to selected brain regions, related to the psychotic symptoms, sparing the ones linked to the motor symptoms; these are due to an antagonist action on 5-HT2A receptors as well, or to a shorter blockage of D2 receptors ([@B5]). The use of antipsychotic drugs to treat agitation tracks back to the 60s ([@B10]); since then, due to increasing evidences of safety concerns, their prescription has been widely reduced ([@B10]).

### Atypical Antipsychotic Drugs {#s1_1_1}

Risperidone is a dopamine, serotonin, and noradrenalin receptor antagonist ([@B4]), licensed for the treatment of maniac and mixed bipolar disorder episodes and is approved for short-term treatment of behavioral symptom in dementia in UK, but not in the US ([@B4]). Several clinical trials evaluated the efficacy of risperidone in the treatment for BPSD. A significant improvement in aggression, measured with the BEHAV-AD (Behavioural Pathology in Alzheimer's Disease) scale, was seen with risperidone at 1 and 2 mg, with better outcome on the higher dose (--1.50 \[--2.05, --0.95\] p \< 0.0001), compared to placebo ([@B11]; [@B9]). Some difference was also seen at the dose of 1 mg, compared to placebo, in treating psychosis (--0.14 \[--0.25, --0.03\] p = 0.01) ([@B11]; [@B9]). The largest randomized controlled study (RCT) "Cognitive Effects of A typical Antipsychotic Medications in Patients with Alzheimer's Disease" (CATIE-AD) gave interesting results. A cohort of 421 patients with AD, followed up in an outpatient setting for psychosis or agitation/aggression, was randomized to receive placebo, risperidone, quetiapine, or olanzapine for 36 weeks, with cognitive assessment at baseline, 12, 24, and 36 weeks ([@B12]). The risperidone or olanzapine groups showed greater cognitive decline in the cognitive summary score (sum of 18 cognitive tests), while the olanzapine one had a greater decline in the mini mental state examination (MMSE); the BPRS cognitive factor was worse in quetiapine group, compared to the placebo group ([@B12]). The phase 1 outcomes of CATIE-AD showed that, compared to placebo, the group receiving risperidone had greater improvement in the Brief Psychiatric Rating Scale (BPRS) psychosis factor and in the Clinical Global Impression of Changes (CGI-C) ([@B13]). The groups receiving either risperidone or olanzapine had greater improvement in the Neuropsychiatric Inventory scale (NPI) and BPRS hostile suspiciousness factor ([@B13]). However, the final results of the study did not show any significant advantages in the improvement in the CGI-C scale; adverse event and discontinuation due to poor tolerability favoured placebo ([@B14]). The multicentre Antipsychotic Discontinuation in Alzheimer's disease (ADAD) trial evaluated a cohort of 180 patients with AD and agitation or psychosis. The whole cohort received risperidone for 16 weeks, and then was randomized to proceed with risperidone for 32 weeks, receive risperidone for 16 weeks and placebo for further 16 weeks, or receive placebo for 32 weeks ([@B15]). The discontinuation of the drug led to increased risk of relapse during the randomization window, particularly for severe hallucinations at baseline ([@B15]). The dementia antipsychotic withdrawal trial (DART-AD) randomized patients with AD in care facilities to continue the current medication (thioridazine, chlorpromazine, haloperidol, trifluoperazine, or risperidone) or switch to placebo for 12 months ([@B16]), with mortality rate as a primary outcome. Among the whole cohort, the mortality was higher in the subject continuing the medication, compared to the placebo branch ([@B16]).

Olanzapine is an atypical antipsychotic, licensed for the treatment of schizophrenia and bipolar disorder in adults. Studies have been conducted to evaluate the efficacy in controlling behavioral symptoms in dementia. De Deyn et al. conducted a large study with \> 600 AD patients with delusions or hallucinations, randomized to receive either placebo or a fixed dose of olanzapine (1.0, 2.5, 5.0, or 7.5 mg/day) for 10 weeks. An improvement in the sum of delusion and hallucination scores of the NPI was seen in the group treated, from the 2.5 mg dose, with higher efficacy for the 7.5 mg dose ([@B17]). Another study compared the efficacy and tolerability of a flexible dose of olanzapine and risperidone vs. placebo in the NPI and Clinical Global Impression--Severity (CGI-S) of Psychosis scale. Improvement has been noticed in all the three groups, with a higher rate of adverse events and withdrawal in the risperidone and olanzapine group ([@B18]). In a multicentre, double-blinded and placebo-controlled trial, 206 older patients AD patients in nursing home, showing psychotic or behavioral symptoms, were randomized to receive olanzapine (5, 10, or 15 mg/die) or placebo. Significant improvement in the summed scores of agitation/aggression, delusion and hallucination items in the NPI-nursing home version (NPI-NH) was seen in patient treated with lower doses of olanzapine, while the higher dose did not differ from the placebo. Six weeks treatment with either placebo or three different doses of olanzapine favoured the use of lower doses in controlling behavioral symptoms, compared to placebo or 15mg/day. The treatment was well tolerated. Apart from somnolence and gait disturbances, commoner in the treatment group, no other potential side effects were seen compared to placebo ([@B19]).

Aripiprazole is an atypical antipsychotic drug licensed for the treatment of schizophrenia in adults and adolescents, mania in bipolar disease in children, adolescents and adults, autism, major depression in adults. Due to the safer profile, a broader use has been done, including psychosis in older patients with dementia ([@B5]). A 10 weeks double blind, placebo-controlled and multicentre study randomized 208 AD patients with delusions or hallucination, to receive aripiprazole 2 mg/day, possibly titrated to higher dosages, or placebo. Significant improvement was seen in the CGI-S of illness, and in the mean CGI-improvements, in patients more severely affected. Significant improvement has also been demonstrated in the BPRS psychosis and BPRS core scores, but the overall conclusion was that the improvement was only modest over placebo ([@B20]). A double-blind, multicentre and placebo-controlled study assigned institutionalized AD patients with psychotic symptoms to aripiprazole (2, 5 or 10 mg/day) or placebo, for 10 weeks. Significant improvement in the NPI-NH psychosis, delusion, agitation/aggression, anxiety, and irritability subscales was seen in the 10 mg treatment group. Some improvement was also seen in the Cohen-Mansfield Agitation Inventory (CMAI) scores in the 5 and 10 mg group, and the mean CGI-S was better in the 10 mg group ([@B21]). The higher efficacy of 10 mg of aripiprazole in controlling behavioral symptoms has been confirmed in another multicentre, placebo-controlled trial on institutionalized AD patients ([@B22]).

Quetiapine is licensed for the treatment of schizophrenia and bipolar disorder in adults, prescribed off-label to treat post-traumatic stress disorder, anxiety, insomnia, and behavioral symptoms in dementia. Two different doses of quetiapine (100 or 200 mg/daily) vs. placebo tested in a cohort of AD patients showed greater improvement, at a dose of 200 mg, in the Positive and Negative Syndrome Scale (PANSS)-Excitement Component (EC) score, as well as in the CGI-C (observation analysed as Last Observation Carried Forward (LOCF): p = 0.014 and Observed cases (OC): p = 0.002). No advantages over placebo at lower dose ([@B23]). Quetiapine did not show any benefit compared to placebo or other antipsychotic drugs in the CATIE-AD study ([@B12]). Another RCT compared quetiapine, rivastigmine, and placebo over 26 weeks in institutionalized AD patients; the endpoint was the improvement in agitation, measured with the CMAI scale, and cognition ([@B24]). Neither rivastigmine nor quetiapine showed significant benefit compared to placebo, and quetiapine was associated with worse cognitive decline ([@B24]). [**Table 1**](#T1){ref-type="table"} summarizes the above-mentioned studies. Overall, a meta-analysis by Ma et al. pooling RCTs with different antipsychotics, demonstrated their higher efficacy as assessed with NPI, CGI-C, CGI-S, BPRS, and CMAI, compared to placebo ([@B25]).

###### 

The table summarizes the studies on atypical antipsychotic drugs included in the review

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drug           Comparison groups, study design                                           Dose                                                              Outcome                                                                                                                                                                                                          AE                                                                                                                                     Ref
  -------------- ------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------
  Risperidone    Risperidone vs. Placebo, randomized double blind, placebo controlled      1 and 2 mg 0.5 mg                                                 BEHAV-AD scale p \< 0.0001 at 2 mg BEHAV-AD psychosis sub-scale p = 0.01 at 1 mg                                                                                                                                 Dose dependent: EPS Somnolence Mild peripheral oedema for 2mg \> 1mg. EPS at 1 mg NS \> than placebo                                   ([@B11])

                 Risperidone vs. placebo/randomised controlled                             Flexible dose                                                     (-) BPRS                                                                                                                                                                                                         Reported elsewhere                                                                                                                     ([@B12])

                 Risperidone vs. Placebo, double blind, placebo controlled                 Flexible dose                                                     (+) BPRS psychosis factor (p = 0.01) and CGI (p \< 0.001) (+) NPI total score (p = \< 0.001) and BPRS suspiciousness factor (p = 0.003)                                                                          Higher withdrawn depression factor in Olanzapine group (p = 0.03)                                                                      ([@B13])

                 Risperidone or olanzapine vs. placebo, double blind, placebo controlled   0.5 mg or 2.5 mg                                                  (+) NPI and CGI-S of Psychosis                                                                                                                                                                                   Higher rate of EPS symptoms and increased prolactin levels compared to olanzapine or placebo                                           ([@B14])

  Olanzapine     Olanzapine vs. placebo, double blind, placebo controlled                  Flexible dose                                                     (-) BPRS                                                                                                                                                                                                         Greater cognitive decline                                                                                                              ([@B12])

                 Olanzapine vs. placebo, double blind, placebo controlled                  Flexible dose                                                     (+) NPI total score (p = 0.007) and BPRS suspiciousness factor (p = 0.006)                                                                                                                                       Higher withdrawn depression factor in Olanzapine group (p = 0.03)                                                                      ([@B13])

                 Olanzapine vs. placebo, double blind, placebo controlled                  1mg, 2.5 mg, 5 mg or 7.5 mg                                       (+) NPI/NH Psychosis Total scores in all groups (p \< 0.001). (+)NPI/NH Psychosis Total scores at 7.5 mg (p = 0.008) and CGI-C at 2.5 (p = 0.030).                                                               Significant overall treatment-group differences in weight gain, Anorexia or and urinary incontinence. NS increase in EPS or total AE   ([@B13])

                 Olanzapine vs. placebo, multicentre double blind, placebo controlled      5mg, 10 mg or 15 mg                                               (+) Summed score of agitation/aggression, delusion and hallucination items in the NPI-NH with 5 or 10 mg (p \< 0.001 and p = 0.006 respectively)                                                                 Higher somnolence and gait disturbances in the olanzapine group. NS difference in EPS or anticholinergic effects                       ([@B19])

                 Olanzapine or risperidone vs. placebo, double blind, placebo controlled   2.5 mg or 10 mg                                                   (+) NPI CGI-S of Psychosis                                                                                                                                                                                       Higher weight gain compared to risperidone or placebo, NS                                                                              ([@B14])

  Aripiprazole   Aripiprazole vs. placeb, double blind, placebo controlled, multicentre    2 mg titrated according to tolerability to 5 mg, 10 mg or 15 mg   (+) in NPI psychosis subscale in treated and placebo group, NS (+)CGI-S, in patients more severely affected (p = 0.035). (+) BPRS psychosis (p = 0.029) and BPRS core scores (p = 0.042)                         Higher urinary tract infections, somnolence and bronchitis. NS difference in EPS or weight gain                                        ([@B20])

                 Aripiprazole vs. placebo, double blind, placebo controlled, multicentre   2mg, 5mg or 10 mg                                                 (+) in NPI-NH psychosis subscale (p = 0.013), CGI-S (p = 0.030), BPRS Core (0.007), CMAI (p = 0.023) and NPI-NH Psychosis response rate (p = 0.019) at 10 mg. (+) in BPRS and CMAI at 5 mg No efficacy at 2 mg   Cerebrovascular events increasing with dose.                                                                                           ([@B21])

                 Aripiprazole vs. placebo, placebo controlled, multicentre                 2 mg to be titrated to 5, 10 or 15 mg                             NS in NPI-NH psychosis score (p = 0.08) or CGI-S (p = 0.19). Improvement in NPI-NH total score, BPRS, CMAI, Cornell Depression scale.\                                                                           Higher somnolence in treatment group                                                                                                   ([@B22])
                                                                                                                                                             (+) in CGI-S was seen in more severely affected patients                                                                                                                                                                                                                                                                                                

  Quetiapine     Quetiapine vs. placebo, double blind, fixed dose study                    100 mg or 200 mg                                                  (+) in PANNS-EC (OC p = 0.014) and CGI-C (OC p = 0.002) at 200 mg.\                                                                                                                                              Mortality numerically higher in the quetiapine group                                                                                   ([@B23])
                                                                                                                                                             No difference with placebo at 100 mg                                                                                                                                                                                                                                                                                                                    

                 Quetiapine vs. placebo, double blind, placebo controlled                  Flexible dose                                                     No benefit                                                                                                                                                                                                       Greater cognitive decline                                                                                                              ([@B12])

                 Quetiapine vs. placebo, randomised, placebo controlled                                                                                      No improvement in agitation inventory scores                                                                                                                                                                     Significantly greater cognitive decline                                                                                                ([@B24])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BEHAV-AD, Behavioural Pathology in Alzheimer's Disease; BPRS, Brief Psychiatric Rating Scale; NPI, Neuropsychiatric Inventory; NPI/NH, nursing home version; CGI-S, Clinical Global Impression--Severity; CGI-C, Clinical Global Impression of Changes; CMAI, Cohen-Mansfield Agitation Inventor; PANNS-EC, Positive and Negative Syndrome Scale (PANSS)-Excitement Component (EC).

Antipsychotics and Safety {#s1_2}
-------------------------

Neuroleptic drugs have been related to several adverse event and safety issues. The increasing concerns about adverse events and tolerability led the FDA to include a warning, in the form of a "black box" in the atypical and typical antipsychotic labels, to limit the prescription ([@B26]). The warning has also been issued by the European Medicines Agency (EMA); the committee for Medicinal Products for Human Use recommended including a warning of increased risk of death for all conventional antipsychotics in the older patients with dementia. Among the most frequent and widely reported side effect of neuroleptic, drowsiness, tardive dyskinesia and parkinsonism have been reported ([@B9]). Moreover, increased risk of venous thromboembolic events (VTE) has been demonstrated in patients treated with antipsychotics, both in general and older population ([@B27]). In a meta-analysis in 2006, Ballard *et al*. reported several side effects of neuroleptics; haloperidol, among the first generation ones, was associated with EPS and drowsiness ([@B9]). A systematic review aiming to compare the rates of EPS with second generation antipsychotic drugs with the first-generation ones, confirmed a reduced incidence with the former, across different pathologies and age groups ([@B28]). Among atypical neuroleptics, risperidone showed increased EPS at the dose of 1 mg and 2 mg; dose-dependent increase in somnolence and peripheral oedema was also seen in institutionalized AD patients ([@B11]). The higher incidence of EPS, somnolence, urinary tract infection (UTI), has been confirmed in two more recent studies, among nursing home residents with AD, vascular dementia or mixed ([@B29]). Gait disturbances and somnolence were also more common in patients treated with olanzapine compared to placebo ([@B19]). Moreover, the impact on cardiovascular system is also a concern. In particular, elongation of the QT interval, torsade de pointes (TdP), and sudden cardiac death have a known relationship with antipsychotic drugs ([@B30]). A case control study on a population aged 65 years or above, undertaking antipsychotics at possible or conditional risk of TdP, demonstrated higher TdP risk for drugs classified as "known TdP risk, " with risk ranking of haloperidol \> risperidone \> olanzapine \> quetiapine ([@B31]). The risk of VTE is estimated to be double, compared to the general population, especially within the first three months of therapy, and several mechanisms are potentially responsible for this association. The reduced physical activity of older patients seems to play a role and, risk increases when associating more than one neuroleptic ([@B32]). Patients receiving typical antipsychotics have been reported to have elevated levels of antiphospholipid antibodies (including anticoagulants and anticardiolipin antibodies), which are associated with an increased VTE risk. Moreover, atypical antipsychotics may cause metabolic syndrome, which is per se a VTE risk factor ([@B32]).

Increased incidence of cerebrovascular disease has been demonstrated in randomized controlled studies in older patients ([@B33]), although the matter is debated. A recent meta-analysis demonstrated a more than doubled risk of stroke in general population using antipsychotics, which although appears to be lower in population with dementia. No association was seen with myocardial infarction, although the heterogeneity of the available studies limits the strength of the conclusion ([@B34]). The meta-analysis by Ma et al., together with the efficacy of the antipsychotic therapy, showed higher risk for adverse events, such EPS (OR 1.74), cerebrovascular events (OR 2.5), somnolence (OR 2.95), gait disturbances (OR 3.35), oedema (OR 1.8), UTI (OR 1.35), and death (OR 1.52) ([@B25]). A large meta-analysis was published in 2018, including more than 380,000 patients with dementia, including more than 80,000 using antipsychotics, and 359,235 patients without dementia ([@B35]). The results showed the HR (hazard ratio) for all-cause mortality in patients treated with antipsychotic drugs 1.9--2.19, with higher risk within the first 180 days, and dose related. The risk was similar in subjects with and without dementia ([@B35]).

Treating patients with dementia often means treating older patients, presenting with polypathology, polypharmacy, and different sensitivity to the effect of psychotropic drugs. For this reason, potential drug drug-drug interaction needs to be considered ([@B36]). Taken together, the need of new therapeutic options, with a safer profile, is urgently needed, to better address such a delicate problem like the management of older patients and often frail patients.

Different Approaches and New Options {#s1_3}
------------------------------------

Different pharmacological approaches for the treatment of behavioral symptoms have been evaluated.

Acetylcholinesterase inhibitors (AChEI) demonstrated a mild effect on BPSD, particularly on agitation, delusion, aggression, or hallucination ([@B37]); more benefits have been seen in Lewy Body dementia-related hallucinations ([@B3]). A recent meta-analysis demonstrated the efficacy of memantine in controlling "positive" symptoms such as aggression, agitation, delusions, disinhibition, compared to control; it was also effective on hallucinations ([@B38]). The combined use of AChEI+memantine has been evaluated in a meta-analysis by Matsunaga et al; the results showed a better outcome of the combined therapy compared to AChEI alone in both behavioral and functional scores, with also a positive trend in cognitive performance ([@B39]). A further meta-analysis confirmed the better outcome in terms of both cognitive and behavioral symptoms of the combined therapy ([@B40]).

Among selective serotonin uptake inhibitors, sertraline showed some efficacy in a cohort of patients with mild to moderate agitation; citalopram gave good results on agitation in the face, however, of possible QTc prolongation. ([@B4]). When compared to atypical antipsychotic, such as perphenazine, risperidone, or quetiapine, improvement in agitation has been seen, with less adverse event for the citalopram-treated group ([@B41]). Trazodone has been tested as well; reduction in agitation could be a consequence of sedation due to its histaminergic effect ([@B4]). Anticonvulsants, such as carbamazepine and gabapentin, showed some potential effects, however in case reports or small and not RCT trials ([@B3]; [@B4]).

An algorithm for the therapeutic approach to agitation and aggression in patients with AD or mixed dementia, revised by a multidisciplinary team, was recently proposed ([@B4]). The algorithm hypothesizes a sequential use of medication, basing on evidences, efficacy, safety and tolerability. Risperidone is the first step of treatment ([@B4]), followed by quetiapine or aripiprazole; titration and switching-drug time-point are also suggested. ([@B4]).

Atypical antipsychotic drugs, such as primavanserin, lumateperone, and brexpiprazole, are currently under evaluation. Primavanserin, approved for the treatment of hallucinations and delusions in Parkinson's disease, works reducing the baseline activity of 5HT2A receptors, which are upregulated in psychotic symptoms, mediating the effects of 5HT2C without antagonizing D2 receptors. A phase II, double blind, placebo-controlled study in UK showed significant improvement in the NPI-NH psychosis score in the treatment group compared to placebo, at 6 weeks of treatment ([@B41]). However, concerns were raised about the reliability of the results, due to the small effect, only observed at 6 weeks, and the potential safety issues ([@B42]). Nonetheless, another double blind, placebo-controlled study is undergoing to evaluate its efficacy in preventing relapse of psychotic symptoms ([@B41]). A phase III double blind, placebo-controlled study in AD patients with clinically significant agitation, is currently undergoing with lumateperone, a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems ([@B43]). Brexpiprazole, a novel serotonin-dopamine receptor modulator with partial agonist activity at serotonin~1A~ and dopamine~2/3~ receptors, has been approved for the treatment of schizophrenia and major depressive disorders ([@B43]). Two Phase III, randomized, double blind, placebo-controlled studies were conducted in AD patients with agitation; only one showed improvement in the CMAI scores. However, a further Phase III study is ongoing ([@B41]).

Conclusions {#s2}
===========

AD is a growing healthcare, social, and economic problem. The increased life expectancy with the consequent progressive population ageing lead to higher incidence and prevalence of age-related, chronic diseases, mirrored by the complexity of older patients. Despite the improved diagnostic approach to AD, no disease-modifying medications exist. Behavioral symptoms represent part of the complexity of dementia, and are related to worse cognitive outcome; their treatment is particularly challenging, especially when facing complex and frail patients. Nonetheless, non-pharmacological treatments have shown promising effects in reducing behavioral and psychological symptoms of dementia. Among the available treatments licensed for psychiatric diseases, only risperidone is approved in Europe for behavioral disorders in dementia; other antipsychotics are prescribed "off label." However, some trials are currently undergoing with new potential medications with safer profile.
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